Physician profile
David L Cheng
NPI 1174589766
$11,076.73
in general payments reported to CMS, 2019-2025
41 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,001 · 2020: $4,322 · 2021: $1,012 · 2022: $673 · 2023: $1,098 · 2024: $827 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,123.96 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $803.66 | 2019-2025 | Provenge |
| Pfizer INC. | $548.88 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $465.93 | 2019-2025 | |
| Astellas Pharma US INC | $447.25 | 2019-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $440.62 | 2020-2025 | Botox |
| Myriad Genetic Laboratories, INC. | $427.60 | 2021-2023 | Prolaris |
| Merck Sharp & Dohme LLC | $321.41 | 2021-2025 | Keytruda, Lynparza |
| Sumitomo Pharma America, INC. | $318.30 | 2023-2025 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals LP | $267.86 | 2021-2025 | Lynparza |
| Myovant Sciences INC. | $217.01 | 2021-2022 | |
| Janssen Biotech, INC. | $210.45 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Caris Mpi, INC. | $157.07 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $134.22 | 2022-2025 | |
| Coloplast Corp | $125.53 | 2019-2025 | Speedicath, Porges Coloplast |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.